Meningococcal Disease Vaccine Global Market Report 2025

Description

The meningococcal disease vaccine is designed to protect against meningococcal disease, a severe bacterial infection caused by Neisseria meningitidis. This illness can result in meningitis, which is the inflammation of the membranes surrounding the brain and spinal cord, as well as septicemia, a serious bloodstream infection both of which can be life-threatening.

There are several main types of meningococcal vaccines conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines work by linking bacterial sugars to proteins, thereby enhancing the immune response and providing effective protection against serogroups A, C, W, and Y. These vaccines are particularly recommended for adolescents and individuals at higher risk. They are available for a range of age groups, including infants, children, adults, and the elderly, and are used for various purposes such as routine prevention, post-exposure prophylaxis, travel immunization, and in response to outbreaks. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, with end-users comprising hospitals, specialty clinics, home care services, and additional healthcare settings.

The meningococcal disease vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal disease vaccines market statistics, including the meningococcal disease vaccines industry global market size, regional shares, competitors with the meningococcal disease vaccines market share, detailed meningococcal disease vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the meningococcal disease vaccines industry. This meningococcal disease vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The meningococcal disease vaccine market size has grown rapidly in recent years. It will grow from$2.37 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to enhanced vaccine manufacturing capabilities, the establishment of global health partnerships, incorporation into national immunization programs, an increase in meningococcal disease cases, and intensified efforts by various organizations.

The meningococcal disease vaccine market size is expected to see rapid growth in the next few years. It will grow to$3.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth projected for the forecast period can be attributed to rising awareness of preventive healthcare, the expansion of target age groups, the entry of new market participants, stockpiling initiatives by governments and health agencies in preparation for potential outbreaks, and increasing public education efforts. Key trends expected during this period include advancements in vaccine technology, the development of multivalent, conjugate, and protein-based vaccines, global trends in travel and migration, increased research and development in mRNA technology, and innovations in thermostable vaccine formulations.

The growth of the meningococcal disease vaccine market is being driven by the rise in government immunization programs. These programs are public health initiatives that provide free or affordable vaccines to protect populations against infectious diseases. The expansion of these programs stems from a stronger focus on disease prevention and reducing the burden on healthcare systems through widespread vaccination efforts. By increasing access to vaccines and boosting immunization rates, these programs help raise public awareness and lower disease incidence. They also generate demand through vaccination mandates and public health campaigns. For example, in April 2024, the Pan American Health Organization (PAHO), a US-based specialized agency, launched the 22nd Vaccination Week in the Americas (VWA) under the theme "Engage now to protect your future. GetVax." The campaign aimed to boost vaccine coverage, particularly in underserved communities, by administering over 65 million doses. The initiative targeted misinformation and improved vaccine access through community outreach and customized campaigns. As a result, growing government immunization efforts are fueling the expansion of the meningococcal disease vaccine market.

Leading players in the meningococcal disease vaccine market are focusing on the development of advanced vaccines, such as pentavalent formulations, to broaden serogroup protection, simplify vaccination schedules, and enhance disease prevention. A pentavalent meningococcal vaccine offers immunization against five major serogroups of Neisseria meningitidis in a single dose, minimizing the need for multiple injections and improving vaccine compliance. For instance, in October 2023, Pfizer Inc., a US-based biopharmaceutical firm, received FDA approval for PENBRAYA, the first and only vaccine approved for preventing meningococcal disease in individuals aged 10 to 25 years. This groundbreaking vaccine merges elements from two existing vaccines, Trumenba and Nimenrix, to safeguard against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis, which are responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. PENBRAYA marks a major leap in disease prevention by offering the widest serogroup coverage among U.S.-available vaccines and potentially reducing the total number of required doses for complete protection.

In September 2023, Biovac, a biopharmaceutical company based in South Africa, joined forces with EuBiologics Co. Ltd. to enhance Africa's capacity for vaccine innovation and self-reliance. This collaboration is focused on technology transfer and the local production of a pentavalent meningococcal conjugate vaccine in Africa. The initiative seeks to meet urgent healthcare demands in the meningitis belt and promote regional vaccine manufacturing capabilities. EuBiologics Co., Ltd., based in South Korea, specializes in the production of pentavalent meningococcal conjugate vaccines.

Major players in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, and Immunopreparat.

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in meningococcal disease vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the meningococcal disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Meningococcal Disease Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on meningococcal disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for meningococcal disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The meningococcal disease vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Vaccine Type: Conjugate Vaccines; Polysaccharide Vaccines; Recombinant Vaccines; Live Attenuated Vaccines
2) By Age Group: Infants; Children; Adults; Older Adults
3) By Indication: Preventive Vaccination; Post-Exposure Prophylaxis; Travel-Related Vaccination; Outbreak Response
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Conjugate Vaccines: Monovalent Conjugate Vaccines; Quadrivalent Conjugate Vaccines; Pediatric Conjugate Vaccines; Adolescent Or Adult Conjugate Vaccines
2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines; Trivalent Polysaccharide Vaccines; Quadrivalent Polysaccharide Vaccines; Age-Specific Polysaccharide Formulations
3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines; Multicomponent Recombinant Vaccines; Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines; Genetically Engineered Attenuated Strain Vaccines; Combined Live Attenuated Vaccines
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; Novartis AG; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35508

1. Executive Summary

2. Meningococcal Disease Vaccine Market Characteristics

3. Meningococcal Disease Vaccine Market Trends And Strategies

4. Meningococcal Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Meningococcal Disease Vaccine Growth Analysis And Strategic Analysis Framework

5.1. Global Meningococcal Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Meningococcal Disease Vaccine Market Growth Rate Analysis
5.4. Global Meningococcal Disease Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Meningococcal Disease Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Meningococcal Disease Vaccine Total Addressable Market (TAM)

6. Meningococcal Disease Vaccine Market Segmentation

6.1. Global Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Conjugate Vaccines
Polysaccharide Vaccines
Recombinant Vaccines
Live Attenuated Vaccines
6.2. Global Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infants
Children
Adults
Older Adults
6.3. Global Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preventive Vaccination
Post-Exposure Prophylaxis
Travel-Related Vaccination
Outbreak Response
6.4. Global Meningococcal Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.5. Global Meningococcal Disease Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-Users
6.6. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monovalent Conjugate Vaccines
Quadrivalent Conjugate Vaccines
Pediatric Conjugate Vaccines
Adolescent Or Adult Conjugate Vaccines
6.7. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Polysaccharide Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bivalent Polysaccharide Vaccines
Trivalent Polysaccharide Vaccines
Quadrivalent Polysaccharide Vaccines
Age-Specific Polysaccharide Formulations
6.8. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Serogroup B Recombinant Protein Vaccines
Multicomponent Recombinant Vaccines
Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
6.9. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Experimental Intranasal Live Attenuated Vaccines
Genetically Engineered Attenuated Strain Vaccines
Combined Live Attenuated Vaccines

7. Meningococcal Disease Vaccine Market Regional And Country Analysis

7.1. Global Meningococcal Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Meningococcal Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Meningococcal Disease Vaccine Market

8.1. Asia-Pacific Meningococcal Disease Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Meningococcal Disease Vaccine Market

9.1. China Meningococcal Disease Vaccine Market Overview
9.2. China Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Meningococcal Disease Vaccine Market

10.1. India Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Meningococcal Disease Vaccine Market

11.1. Japan Meningococcal Disease Vaccine Market Overview
11.2. Japan Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Meningococcal Disease Vaccine Market

12.1. Australia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Meningococcal Disease Vaccine Market

13.1. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Meningococcal Disease Vaccine Market

14.1. South Korea Meningococcal Disease Vaccine Market Overview
14.2. South Korea Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Meningococcal Disease Vaccine Market

15.1. Western Europe Meningococcal Disease Vaccine Market Overview
15.2. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Meningococcal Disease Vaccine Market

16.1. UK Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Meningococcal Disease Vaccine Market

17.1. Germany Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Meningococcal Disease Vaccine Market

18.1. France Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Meningococcal Disease Vaccine Market

19.1. Italy Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Meningococcal Disease Vaccine Market

20.1. Spain Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Meningococcal Disease Vaccine Market

21.1. Eastern Europe Meningococcal Disease Vaccine Market Overview
21.2. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Meningococcal Disease Vaccine Market

22.1. Russia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Meningococcal Disease Vaccine Market

23.1. North America Meningococcal Disease Vaccine Market Overview
23.2. North America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Meningococcal Disease Vaccine Market

24.1. USA Meningococcal Disease Vaccine Market Overview
24.2. USA Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Meningococcal Disease Vaccine Market

25.1. Canada Meningococcal Disease Vaccine Market Overview
25.2. Canada Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Meningococcal Disease Vaccine Market

26.1. South America Meningococcal Disease Vaccine Market Overview
26.2. South America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Meningococcal Disease Vaccine Market

27.1. Brazil Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Meningococcal Disease Vaccine Market

28.1. Middle East Meningococcal Disease Vaccine Market Overview
28.2. Middle East Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Meningococcal Disease Vaccine Market

29.1. Africa Meningococcal Disease Vaccine Market Overview
29.2. Africa Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Meningococcal Disease Vaccine Market Competitive Landscape And Company Profiles

30.1. Meningococcal Disease Vaccine Market Competitive Landscape
30.2. Meningococcal Disease Vaccine Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Meningococcal Disease Vaccine Market Other Major And Innovative Companies

31.1. Hualan Biological Engineering Inc.
31.2. Beijing Tiantan Biological Products Corporation Limited
31.3. Serum Institute of India Pvt. Ltd.
31.4. Walvax Biotechnology Co. Ltd.
31.5. Incepta Pharmaceuticals Ltd.
31.6. CanSino Biologics Inc.
31.7. EuBiologics Co. Ltd.
31.8. Biovac Institute
31.9. Shantha Biotech
31.10. Bio-Manguinhos
31.11. Biomed Pvt. Ltd.
31.12. Chengdu Kanghua Biological Products Co. Ltd.
31.13. Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
31.14. Finlay Institute of Vaccines
31.15. Immunopreparat

32. Global Meningococcal Disease Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Meningococcal Disease Vaccine Market

34. Recent Developments In The Meningococcal Disease Vaccine Market

35. Meningococcal Disease Vaccine Market High Potential Countries, Segments and Strategies

35.1 Meningococcal Disease Vaccine Market In 2029 - Countries Offering Most New Opportunities
35.2 Meningococcal Disease Vaccine Market In 2029 - Segments Offering Most New Opportunities
35.3 Meningococcal Disease Vaccine Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer